|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.17 USD | +0.97% |
|
-7.77% | +153.92% |
| May. 07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
| May. 06 | Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday | MT |
ADC Therapeutics SA reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was USD 209.91 million compared to USD 33.92 million a year ago. Net loss was USD 155.8 million compared to USD 230.03 million a year ago.
Basic loss per share from continuing operations was USD 1.99 compared to USD 3 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +153.92% | 397M | |
| +7.77% | 113B | |
| +10.39% | 106B | |
| +0.41% | 22.27B | |
| -11.99% | 22.22B | |
| -5.99% | 19.43B | |
| -37.36% | 17.87B | |
| -5.22% | 17.24B | |
| +6.52% | 14.29B | |
| +36.22% | 12.52B |
ADC THERAPEUTICS SA 